LSE - Delayed Quote GBp

Hikma Pharmaceuticals PLC (HIK.L)

2,022.00

-40.00

(-1.94%)

At close: January 10 at 4:35:17 PM GMT

Is Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?

We recently compiled a list of the U.K. Dividend Aristocrats List: 2024 Rankings by Yield. In this article, we are going to take a look at where Hikma Pharmaceuticals PLC (LON:HIK.L) stands against the other U.K. dividend aristocrats. In recent years, investors have turned away from UK equities, opting instead for global stocks, particularly high-growth options […]

Insider Monkey 14 days ago

HKMPY

^FTSE
Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Have Financials A Role To Play?

Most readers would already be aware that Hikma Pharmaceuticals' (LON:HIK) stock increased significantly by 5.3% over...

Simply Wall St. 23 days ago

HKMPF

HKMPY
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 95% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£37.96 Hikma...

Simply Wall St. last month

HKMPF

HKMPY
Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 2 months ago

NGG

NGGTF

YUMC
With 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Simply Wall St. 3 months ago

HKMPF

HKMPY
Hikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years ago

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...

Simply Wall St. 4 months ago

HKMPF

HKMPY
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia. This important educational event took place at Groves High School in Savannah, Ga. ahead of National Fentanyl Awareness and Prevention Day.

PR Newswire 4 months ago

HKMPF

HKMPY
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. KLOXXADO® packaging has been updated with 36-month dating, starting with product manufactured in March 2024.

PR Newswire 4 months ago

HKMPF

HKMPY
We Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are Conservative

When companies post strong earnings, the stock generally performs well, just like Hikma Pharmaceuticals PLC's ( LON:HIK...

Simply Wall St. 4 months ago

HKMPF

HKMPY
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know

Hikma Pharmaceuticals (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

HKMPY
Hikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Hikma Pharmaceuticals PLC ( LON:HIK ) investors will be delighted, with the company turning in some strong numbers with...

Simply Wall St. 4 months ago

HKMPF

HKMPY
Hikma Pharmaceuticals First Half 2024 Earnings: Beats Expectations

Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H...

Simply Wall St. 5 months ago

HKMPF

HKMPY
Hikma Pharmaceuticals shares surge on upbeat guidance

Shares of Hikma Pharmaceuticals (OTC:HKMPY) (LON:HIK) jumped on Thursday after the company raised its full-year guidance, buoyed by robust performance in its Branded and Generics divisions. At 5:18 am (0918 GMT), Hikma Pharmaceuticals was trading 7.3% higher at £1,975. “The H1 beat was driven by stronger than anticipated performance from the Branded and Generics divisions, reflected in upgrades to FY guidance ranges for both, while Injectables guidance has been maintained as the company expects an H2 weighting for this division,” analysts at RBC said in a note.

Investing.com 5 months ago

HKMPY
Does The Market Have A Low Tolerance For Hikma Pharmaceuticals PLC's (LON:HIK) Mixed Fundamentals?

It is hard to get excited after looking at Hikma Pharmaceuticals' (LON:HIK) recent performance, when its stock has...

Simply Wall St. 5 months ago

HKMPF

HKMPY
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£29.89 Hikma...

Simply Wall St. 7 months ago

HKMPF

HKMPY
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns

Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Simply Wall St. 8 months ago

HKMPF

HKMPY
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 9 months ago

HKMPY
Merck's Bridion faces generic threat from drugmaker Hikma

Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.

Reuters 10 months ago

HKMPY
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.

PR Newswire 10 months ago

HKMPF

HKMPY
High-dose opioid reversal spray no better than lower dose in field, US study finds

A high-dose version of the opioid reversal spray naloxone, made by Hikma Pharmaceuticals, did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement, according to a U.S. study. The analysis also suggests that those given the higher 8 milligram strength spray were more than twice as likely to experience opioid withdrawal symptoms compared to other sprays such as Narcan that use a 4 mg dose. The Hikma version, sold under the brand name Kloxxado, was approved in 2021 after U.S. Food and Drug Administration advisers and National Institutes of Health reports suggested that a high-dose version was needed to respond to overdoses by more potent opioids such as fentanyl.

Reuters 10 months ago

HKMPY

Performance Overview

Return	HIK.L	FTSE 100
YTD	+1.92%	+1.57%
1-Year	+11.07%	+7.35%
3-Year	+3.66%	+10.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hikma Pharmaceuticals PLC (HIK.L)

Is Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?

Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Have Financials A Role To Play?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 95% Above Its Share Price

Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S

With 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backing

Hikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years ago

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

We Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are Conservative

Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know

Hikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Hikma Pharmaceuticals First Half 2024 Earnings: Beats Expectations

Hikma Pharmaceuticals shares surge on upbeat guidance

Does The Market Have A Low Tolerance For Hikma Pharmaceuticals PLC's (LON:HIK) Mixed Fundamentals?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued

With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns

Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

Merck's Bridion faces generic threat from drugmaker Hikma

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

High-dose opioid reversal spray no better than lower dose in field, US study finds

Performance Overview